Association between paracetamol use during pregnancy and perinatal outcomes: Prospective NISAMI cohort

Caroline Tianeze de Castro; Marcos Pereira; Djanilson Barbosa dos Santos

doi:10.1371/journal.pone.0267270

. 2022 Apr 18;17(4):e0267270. doi: 10.1371/journal.pone.0267270

Association between paracetamol use during pregnancy and perinatal outcomes: Prospective NISAMI cohort

Caroline Tianeze de Castro ^1,^*, Marcos Pereira ², Djanilson Barbosa dos Santos ^1,³

Editor: Linglin Xie⁴

PMCID: PMC9015137 PMID: 35436308

Abstract

Background

Paracetamol is widely used to manage fever and pain during pregnancy worldwide. However, paracetamol may affect the pregnant woman and fetus, once this drug crosses the placental barrier after therapeutic doses and may impair fetal liver function, affecting fetus growth and development. Thus, this study aimed to investigate the association between paracetamol use during pregnancy and perinatal outcomes as preterm birth, low birth weight, and small for gestational age.

Methods and findings

Data from 760 pregnant women within the NISAMI Cohort between June 2012 and February 2014 were analyzed. Logistic regression was used to estimate the association among paracetamol use during pregnancy and preterm birth, low birth weight, and small for gestational age. Multivariate analyses were adjusted for socioeconomic, maternal, pregnancy, and newborn covariates. Around 14% of women were exposed to paracetamol during pregnancy. A decrease in paracetamol use throughout pregnancy was observed. Lower risk of low birth weight in infants born to women exposed to the drug (OR 0.21; IC 95% 0.01–0.99) was found. Paracetamol use during pregnancy was not statistically associated with preterm birth or small for gestational age.

Conclusions

The findings of this study do not suggest an increased risk of perinatal outcomes. However, it should not be assumed that paracetamol is a risk-free medication and its use must be rational.

Introduction

Due to ethical concerns, pregnant women are not included in clinical trials [1]. Therefore, there is insufficient information on the safety and potentially harmful effects of most available drugs on the fetus [2, 3]. Nevertheless, the use of medications during pregnancy is very common to protect the health of the fetus and to treat acute or chronic conditions [4].

Paracetamol is the first-line drug for the treatment of fever and pain in pregnancy [5, 6], available by prescription or for self-medication [7, 8]. The prevalence of paracetamol use during pregnancy ranges from 42.0% to 65.1% [7–10]; in Brazil, it ranges from 13.1% to 72.2% [11–14]. Studies have found high paracetamol use throughout pregnancy, which is not observed with other nonsteroidal anti-inflammatory drugs (NSAID) [15, 16].

Most studies of prenatal paracetamol exposure focusing on congenital malformations [17, 18], stillbirths [19], and miscarriages [19, 20] did not report an increased risk of these outcomes. Evidence on the safety of paracetamol use during fetal development and the impact of high use on perinatal outcomes such as preterm birth, low birth weight, and low gestational age remains scarce and controversial [19, 21–23].

Since paracetamol use during pregnancy can affect both the mother and the fetus once it crosses the placental barrier [24], and considering the high number of pregnant women exposed to this drug worldwide, any impact on perinatal outcomes may have a significant public health impact.

Therefore, this study aimed to investigate the association between paracetamol use during pregnancy and preterm birth, low birth weight, and low gestational age.

Methods

Study design

This is a prospective cohort of pregnant women who received prenatal care in the health clinics of the Brazilian Health System (SUS) in Santo Antônio de Jesus from June 2012 to February 2014. For this study, data from the research project "Maternal risk factors for low birth weight, preterm birth, and intrauterine growth retardation in Recôncavo da Bahia" of the Center for Research in Maternal and Child Health (NISAMI) were used.

Data source

Santo Antônio de Jesus is a city in the Brazilian state of Bahia with 90,985 inhabitants in 2010, of which about 79,299 live in the urban area [25]. Public health services are provided by 21 family health units, 1 primary health unit, and 2 hospitals. Between 1994 and 2017, the average number of live births was 1,413 births per year, with infant and neonatal mortality rates of 11.3/1,000 and 9.2/1,000 inhabitants in 2010, respectively [26].

The study was conducted in all health units in the urban area. Rural health units were excluded due to distance and difficulty of access. Therefore, this cohort included pregnant women of any gestational age from the urban area who were enrolled in the Prenatal Care and Birth Humanization Program Monitoring System (SISPRENATAL).

The sample size calculation of the NISAMI cohort was previously described [11]. In summary, the sample selection was based on a prevalence of 50%, a precision of 4%; confidence level of 95%, and 10% for possible losses. The minimum sample required to ensure statistical significance and 80% power was 891 pregnant women, yet the total sample included 1,091 women.

Data were collected by trained interviewers during prenatal visits. The pregnant women were interviewed using a standardized questionnaire with 116 questions divided into 7 parts: sociodemographic characteristics, nutritional information, gynecological-obstetric and oral health, blood and biochemical tests, medication information (before and during pregnancy), and anthropometry. Obstetric history was obtained from clinical records of prenatal services.

Anthropometric measurements of the newborn (weight, length, and circumferences) were obtained after birth in the Maternity Hospital by the nursing team previously trained for this purpose. The newborn was weighed with a Welmy® brand digital pediatric scale with a capacity of 15 kg and an interval of 10 g, completely naked. A compact Wiso® stadiometer was used to measure the baby’s length. The newborn was laid down with the head supported on the fixed part of the device and the movable part moved to the feet to read the measurement.

Weight and length were measured twice, with a maximum deviation of 10 g for weight and 0.1 cm allowed. A third measurement was taken if larger deviations were found. In these cases, the final measurement was the average of the closest readings [27].

Exposure

Paracetamol use during pregnancy was the exposure variable estimated by three questions, "Have you taken any medications during this pregnancy?" (yes; no), "What medication?" (name; dosage form; dosage), and "Have you taken this medication in the last 15 days?" (yes; no). At the end, the variable was coded as "use of paracetamol in the last 15 days" (yes; no). Pregnant women who had not taken paracetamol during pregnancy were considered unexposed to the drug.

Outcomes

Preterm birth (PTB), low birth weight (LBW), and small for gestational age (SGA) were the outcome variables assessed in this study. PTB was defined as any birth before 37 completed weeks of gestation [28]. LBW was defined as a birth weight of less than 2500 g (5.5 lb) [29]. SGA was defined as a birth weight below the 10th percentile for gestational age [30].

Covariates

Covariates were selected after a literature review and included: mother’s age (≤ 24; 25 to 29; 30 to 35; ≥ 36 years); race/skin color (black; non-black–Asian, white, and Brazilian indigenous); education (≤ 8; 9 to 11; ≥ 11 years); marital status (with a partner; without a partner); employment status (with employment; without employment); family income–according to 2013 minimum wage (MW) (≤ 1 MW; > 1 SM); smoking during pregnancy (yes; no); alcohol use during pregnancy (yes; no); chronic diseases–asthma, diabetes, hypertension, and kidney disease–(yes; no); acute diseases–cytomegalovirus, HTLV, rubella, syphilis, toxoplasmosis, and urinary tract infection–(yes; no); history of PTB (yes; no); history of LBW (yes; no); pre-gestational weight (kilograms); birth order (nulliparous; multiparous); and baby’s sex (male; female).

Statistical analysis

Women’s characteristics and pregnancy outcomes are presented as proportions and 95% confidence intervals (95% CI) for categorical variables and median and interquartile range (IQR) for continuous variables. The normality of data was tested with the Shapiro-Wilk test. Analysis was stratified by paracetamol use during pregnancy (yes; no). Pearson’s chi-square, Fisher’s exact, and Mann-Whitney-Wilcoxon’s tests were used to examine differences between strata.

Logistic regression was used to estimate odds ratios (OR) and 95% CIs for preterm birth, low birth weight, and small for gestational age. Models were adjusted for age, race/skin color, education, marital status, employment status, family income, pre-gestational weight, birth order, and baby’s sex.

R software, version 4.0.4 (R, R Foundation for Statistical Computing, Vienna, Austria) was used for all statistical analyzes.

Ethics statement

The present study was conducted following the Declaration of Helsinki and approved by the Ethics Committee of the Faculdade Adventista de Fisioterapia da Bahia (protocol code: 4369.0.000.070–10; September 14, 2010). Informed consent was obtained from all subjects who participated in the study.

Results

Cohort characteristics

From June 2012 to February 2014, 1,091 pregnant women met the original study selection criteria. A total of 760 (69.7%) women reported taking medication in the 15 days before the interviews and were included in this study. The age of the pregnant women ranged from 14 to 44 years, with a median of 25 years (interquartile range 9.0). About 83.0% of the women were black, 46.6% had up to eight years of education, 83.9% had a partner, and 22.9% had a family income of no more than one minimum wage. Most women did not smoke (95.9%) or use alcohol (82.0%) during pregnancy (Table 1).

Table 1. Characteristics of the study population.

NISAMI Cohort Study, Brazil 2012–2014 (N = 760)*.

	n = 760		Exposed		Unexposed		p-value
	n = 760		(n = 106)		(n = 654)
	n	%	n	%	n	%
Mother age (years)							0.089^a
≤ 24	345	45.4	38	35.8	307	47.0
25 to 29	203	26.8	34	32.1	169	25.9
30 to 35	161	21.2	23	21.7	138	21.1
≥ 36	50	6.6	11	10.4	39	6.0
Median	25.0		27.0		25.0		0.112^c
IQR	9.0		9.0		9.0		0.112^c
Race/Skin color							0.109^a
Non-black	127	16.7	12	11.3	115	17.6
Black	633	83.3	94	88.7	539	82.4
Education (years)							0.048^a
≤ 8	353	46.6	38	35.9	315	48.3
9 to 11	355	46.8	61	57.5	294	45.1
≥ 11	50	6.6	7	6.6	43	6.6
Marital status							0.151^a
Without a partner	122	16.1	12	11.3	110	16.9
With a partner	637	83.9	94	88.7	543	83.1
Employment status							0.412^a
Without employment	383	50.9	50	47.2	333	51.5
With employment	370	49.1	56	52.8	314	48.5
Family income							0.096^a
≤ 1 MW	166	22.9	16	16.3	150	23.9
> 1 MW	559	77.1	82	83.7	477	76.1
Smoking during pregnancy							0.789^b
No	720	95.9	101	97.1	619	95.7
Yes	31	4.1	3	2.9	28	4.3
Alcohol use during pregnancy							0.512^a
No	310	82.0	46	85.2	264	81.5
Yes	68	18.0	8	14.8	60	18.5
Chronic diseases							0.827^a
No	665	88.9	94	89.5	571	88.8
Yes	83	11.1	11	10.5	72	11.2
Acute diseases							0.589^a
No	84	27.9	10	24.39	74	28.5
Yes	217	72.1	31	75.61	186	71.5
History of preterm birth							0.548^a
No	259	86.6	42	89.4	217	86.1
Yes	40	13.4	5	10.6	35	13.9
History of low birth weight							0.071^a
No	237	84.0	41	93.2	196	82.3
Yes	45	16.0	3	6.8	42	17.7
Pre-gestational Body Mass Index (BMI)							0.495^a
Underweight	50	7.3	8	8.2	42	7.1
Eutrophic	410	59.5	52	53.1	358	60.6
Overweight	160	23.2	25	25.5	135	22.8
Obesity	69	10.0	13	13.2	56	9.5
Pre-gestational weight (kg)							0.137^c
Median	59.0		62.0		59.0
IQR	15.0		15.0		16.0
Birth order							0.140^a
Nulliparous	386	51.0	47	44.3	339	52.1
Multiparous	371	49.0	59	55.7	312	47.9
Baby’s sex							0.820^a
Male	392	51.9	56	53.3	337	51.7
Female	364	48.1	49	46.7	315	48.3
Gestational age (weeks)							0.288^c
Median	39.0		39.0		39.0
IQR	2.0		2.0		2.0
Birth weight (g)							0.065^c
Median	3.300.0		3.405.0		3.312.5
IQR	612.5		515.0		605.0
Preterm birth							0.920^a
No	679	89.3	95	89.6	584	89.3
Yes	81	10.7	11	10.4	70	10.7
Low birth weight							0.072^b
No	726	95.5	105	99.1	621	95.0
Yes	34	4.5	1	0.9	33	5.0
Small for gestational age							0.360^a
No	692	93.0	98	95.1	594	92.7
Yes	52	7.0	5	4.9	47	7.3

Open in a new tab

*There are losses in some variables. Acute diseases variable has the greatest loss.

^ap-value calculated by Chi-square test.

^bp-value calculated by Fisher’s exact test.

^cp-value calculated by Mann-Whitney-Wilcoxon’s test.

In this cohort, 106 women (13.9%) were exposed to paracetamol at some time during pregnancy. Women exposed to paracetamol in pregnancy were significantly more likely to have had between nine and 11 years of education compared to women who were not exposed to the drug (57.5% vs. 45.1%; p = 0.048). Other covariates examined did not differ significantly between women exposed to paracetamol and those not exposed (Table 1).

PTB occurred in 10.4% (n = 11) of women exposed to paracetamol versus 10.7% (n = 70) of women unexposed to the drug. LBW was observed in 0.9% (n = 1) of the offspring of women exposed to paracetamol and in 5.0% (n = 33) of the offspring of women unexposed to paracetamol. The prevalence of SGA was 4.8% (n = 5) and 7.3% (n = 47) in exposed and unexposed women, respectively (Table 1).

Paracetamol use and perinatal outcomes

Paracetamol use decreased throughout pregnancy. Eighty-nine women (11.7%) were exposed to the drug during the first trimester, of whom 9.0% had PTB, 1.1% LBW, and 4.5% SGA. Among the 49 women (6.4%) who used the drug during the second trimester, the prevalence of PTB, LBW, and SGA was 16.3%, 2.0%, and 8.2%, respectively. Seven women (0.9%) used paracetamol in the third trimester, of whom none had PTB or LBW and 14.3% had SGA babies (Fig 1).

There was no statistically significant association between paracetamol use during pregnancy and PTB after adjustment (OR 1.02; 95% CI 0.47–2.01). Babies born to women who used paracetamol during pregnancy had a lower risk of LBW in the crude (OR 0.18; 95% CI 0.01–0.85) and adjusted (OR 0.21; 95% CI 0.01–0.99) analyzes. Paracetamol use during pregnancy was not statistically associated with SGA after adjustment (OR 0.72; 95% CI 0.21–1.92) (Table 2).

Table 2. Odds Ratios for preterm birth, low birth weight, and small for gestational age in women exposed to paracetamol during pregnancy.

NISAMI Cohort Study, Brazil 2012–2014.

	Paracetamol ever
	Crude OR	95% CI	Adjusted OR^a	95% CI
Preterm birth	0.97	0.47–1.82	1.02	0.47–2.01
Low birth weight	0.18	0.01–0.85	0.21	0.01–0.99
Small for gestational age	0.64	0.22–1.52	0.72	0.21–1.92

Open in a new tab

^aAdjusted for age, race/skin color, education, marital status, employment status, family income, pre-gestational weight, birth order, and baby’s sex.

Discussion

This study showed that about 14.0% of pregnant women reported paracetamol use at least once during pregnancy. Similarly, a previous Brazilian study found that 13.1% of pregnant women were exposed to paracetamol during pregnancy [14]. In contrast, studies in Spain [6], North America [9], and Norway [10] found a higher prevalence of paracetamol use among pregnant women, 67.4%, 62.0%, and 46.1%, respectively. This difference could be due to the high consumption of metamizole in pregnant women in Brazil [31], an analgesic and antipyretic drug that is not on the market in North America and most European countries [32]. In addition, the low prevalence of paracetamol use in our population could be related to the way the information on medication use was collected, since the pregnant women were interviewed at different times and some of them could answer the medications taken during the entire pregnancy, while others only during part of the pregnancy.

The prevalence of paracetamol use in this study was low in all trimesters, which differs from the available literature [16, 33]. Moreover, a decrease in paracetamol use during pregnancy was observed. Similar results were reported in a Danish study [16], in which the prevalence of paracetamol exposure during the first, second, and third trimesters was approximately 30.0%, 22.4%, and 28.4%, respectively, and in a North American study [15], in which 54.2% of pregnant women used paracetamol in the first trimester, 50.5% in the second trimester, and 48.0% in the third trimester. The decrease in paracetamol use during pregnancy in our population is likely related to switching to other NSAIDs or greater concern with medication use during pregnancy, particularly in the third trimester.

In this cohort, no differences in PTB were observed between groups exposed to paracetamol and those not exposed. Results in the literature on the effects of paracetamol on BP are controversial. Similar to the results of this study, a Canadian prospective cohort with data from 1,200 pregnant women between January 2013 and June 2017 found no differences in PTB between women who were exposed to paracetamol during pregnancy and those who were not [21]. The authors reasoned that the lack of information on paracetamol indication could contribute to confounding, limited generalization, once the pregnant women studied were older and more educated than the Canadian average, and the low prevalence of perinatal outcomes, resulting in low power of the study, and chance findings could be associated with these results.

A Danish prospective cohort study that analyzed data from 13,450 women in 1991 and 1996 also found no statistically significant difference in PTB among pregnant women exposed to the drug (OR 0.59; 95% CI 0.22–1.61) [23]. However, the inability to control for the intended use of paracetamol (fever, acute, and chronic illness) and lack of information on its use may have contributed to the lack of statistical significance.

However, in another Danish prospective cohort study with data from 98,140 pregnant women between 1996 and 2003, an increased risk of PTB was observed in women exposed to paracetamol during the third trimester (HR 1.14; 95% CI 1.03–1.26). This association may be related to the potential of paracetamol to cause preeclampsia by reducing prostacyclin synthesis and subsequently affecting hypertension [19]. A prospective cohort of 68,833 women from Denmark who gave birth to singletons between 1996 and 2003 showed an increased risk of preeclampsia in those exposed to paracetamol in the third trimester (RR 1.40; 95% CI 1.24–1.58) [34].

In contrast, a Hungarian case-control study with data from 38,151 mothers of children born alive between 1980 and 1996 found that exposure to paracetamol during pregnancy reduced the risk of PTB by 60.0% (OR 0.40; 95% CI 0.20–0.80) [22]. The authors argue that this finding may be related to the paracetamol-induced reduction in prostacyclin production, resulting in longer gestational age in neonates exposed to paracetamol during pregnancy. However, interpretation of this finding must take into account study limitations, including memory bias and lack of adjustment for important confounders reported in the literature.

In the present cohort, women exposed to paracetamol during pregnancy had a statistically significant decreased risk of LBW babies. On the other hand, results from LBW on this topic have been inconsistent. A Canadian prospective pregnancy and birth cohort that analyzed data from 1,200 pregnant women from January 2013 to June 2017 observed a reduced but not statistically significant risk for LBW in infants born to mothers who took paracetamol during pregnancy [21].

Otherwise, two studies observed a nonstatistically significant increase LBW in offspring of pregnant women exposed to paracetamol. The first study observed an odds ratio of LBW of 1.05 in paracetamol users during pregnancy (95% CI 0.25–4.31) [23]. The second reported a hazard ratio of LBW in women exposed to the drug of 1.14 (95% CI 0.94–1.31) [19]. The lack of statistical significance in the latter study may be related to the lack of information on daily and sporadic use and control for confounders such as fever, headache, inflammation, and preeclampsia.

Although there is no explicit biological mechanism explaining the association between paracetamol use during pregnancy and a decrease in low birth weight, we hypothesized that the reduction in prostacyclin production caused by paracetamol could lead to tocolytic activity [35] and affect the birth weight of the offspring of women exposed to the drug.

Again, this study did not find a statistically significant association between paracetamol use during pregnancy and SGA. Two prospective cohort studies from Canada [21] and Denmark [19] also found no association between paracetamol exposure during pregnancy and outcome.

Strengths and limitations

Nowadays, there are few studies on this topic in the scientific literature, and this study was the first to analyze the association between paracetamol use during pregnancy and perinatal outcomes in Brazil. In addition, there is limited evidence on the safety of paracetamol use during fetal development and information on the consequences of this high pattern of consumption on perinatal outcomes.

One of the strengths of this study is the use of a standardized and tested questionnaire, standardization of data collection, and data validation. Another strength is the prospective design of the cohort, in which interviews were conducted during the prenatal period rather than only at delivery.

Nevertheless, this study also has some limitations. Considering that paracetamol can be taken both by prescription and self-medication, consumption could be underestimated due to memory bias and underreporting. However, to minimize these biases, only women who reported taking medication 15 days before the interviews were included in the present analysis. In addition, information on the dosage and frequency of paracetamol use was not obtained to clarify its influence on the outcomes. Also, because no information was available on the indication of paracetamol use by pregnant women, the possibility of indication bias exists.

The main limitation of the study was its small size, which may not be sufficient to detect statistically significant differences and limit comparisons with other studies. In addition, the prevalence of perinatal outcomes in the study population was relatively low (PTB: 10.7%; LBW: 4.5%; SGA: 6.8%), which may result in low power and consequent lack of statistical significance.

Although the analyzes were adjusted for several confounding factors, it was not possible to control for preeclampsia because this information was not available. According to previous studies, preeclampsia is a risk factor for the development of perinatal outcomes [36, 37] and the use of paracetamol during pregnancy increases the risk of preeclampsia [34]. In addition, the analyzes were not adjusted for other factors that increase the risk of perinatal outcomes, such as smoking [38, 39] and the use of drugs of abuse [40, 41] during pregnancy, because the number of pregnant women with these habits in the study was very small. In addition, some covariates such as chronic diseases, acute diseases, history of PTB, and history of LBW were not included because a large number of data were missing. Therefore, it is not possible to exclude residual confounding.

Finally, it was not possible to perform analyzes by trimester of exposure because none of the women who had taken paracetamol in the third trimester of pregnancy had PTB or SGA neonates.

Conclusions

In this prospective cohort of pregnant women, paracetamol use was not associated with a lower risk of PTB or SGA. However, a decreased risk for LBW was observed. Given the uncertainty of the biological plausibility and limitations of the study, these results should be further investigated.

Although the present results do not suggest an increased risk of perinatal outcomes, it should not be assumed that paracetamol is a risk-free drug, and its use must be rational, taking into account the clinical needs of the patient, the appropriate dose, and at an appropriate time.

Supporting information

S1 Database

(XLSX)

Click here for additional data file.^{(100.6KB, xlsx)}

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

This research was funded by the Research Foundation of the State of Bahia, grant number 7190/2011, APP0038/2011, and BOL0401/2019 and the National Council for Scientific and Technological Development, grant number 481509/2012-7. The funders had no role in study design, study selection and data extraction, data analysis, decision to publish, or preparation of the manuscript.

References

1.Grzeskowiak LE, Gilbert AL, Morrison JL. Exposed or not exposed? Exploring exposure classification in studies using administrative data to investigate outcomes following medication use during pregnancy. Eur J Clin Pharmacol. 2012;68(5):459–67. doi: 10.1007/s00228-011-1154-9 [DOI] [PubMed] [Google Scholar]
2.Adam MP, Polifka JE, Friedman JMM. Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet Part C Semin Med Genet. 2011;157(3):175–82. doi: 10.1002/ajmg.c.30313 [DOI] [PubMed] [Google Scholar]
3.Daw JR, Hanley GE, Greyson DL, Morgan SG. Prescription drug use during pregnancy in developed countries: a systematic review. Pharmacoepidemiol Drug Saf. 2011. Jul;20(9):895–902. doi: 10.1002/pds.2184 [DOI] [PMC free article] [PubMed] [Google Scholar]
4.Sinclair SM, Miller RK, Chambers C, Cooper EM. Medication Safety During Pregnancy: Improving Evidence‐Based Practice. J Midwifery Womens Health. 2016;61(1):52–67. doi: 10.1111/jmwh.12358 [DOI] [PubMed] [Google Scholar]
5.Allegaert K, van den Anker JN. Perinatal and neonatal use of paracetamol for pain relief. Semin Fetal Neonatal Med. 2017;22(5):308–13. doi: 10.1016/j.siny.2017.07.006 [DOI] [PubMed] [Google Scholar]
6.Castillo Barrio B, Bravo Laguna MC, de la Calle Fernández M, Pellicer Martínez A. Consumption of paracetamol during pregnancy. An Pediatr. 2020;93(3):196–7. doi: 10.1016/j.anpedi.2019.12.016 [DOI] [PubMed] [Google Scholar]
7.Benevent J, Hurault-Delarue C, Araujo M, Montastruc JL, Lacroix I, Damase-Michel C. POMME: The New Cohort to Evaluate Long-Term Effects After Prenatal Medicine Exposure. Drug Saf. 2019;42(1):45–54. doi: 10.1007/s40264-018-0712-9 [DOI] [PubMed] [Google Scholar]
8.Volqvartz T, Vestergaard AL, Aagaard SK, Andreasen MF, Lesnikova I, Uldbjerg N, et al. Use of stimulants, over‐the‐counter and prescription drugs among Danish pregnant women. Basic Clin Pharmacol Toxicol. 2020;bcpt.13396. doi: 10.1111/bcpt.13396 [DOI] [PubMed] [Google Scholar]
9.Bandoli G, Palmsten K, Chambers C. Acetaminophen use in pregnancy: Examining prevalence, timing, and indication of use in a prospective birth cohort. Paediatr Perinat Epidemiol. 2020;34(3):237–46. doi: 10.1111/ppe.12595 [DOI] [PMC free article] [PubMed] [Google Scholar]
10.Ystrom E, Gustavson K, Brandlistuen RE, Knudsen GP, Magnus P, Susser E, et al. Prenatal Exposure to Acetaminophen and Risk of ADHD. Pediatrics. 2017;140(5):e20163840. doi: 10.1542/peds.2016-3840 [DOI] [PMC free article] [PubMed] [Google Scholar]
11.Costa DB, Coelho HLL, Santos DB. Utilização de medicamentos antes e durante a gestação: prevalência e fatores associados. Cad Saude Publica. 2017;33(2). [DOI] [PubMed] [Google Scholar]
12.Tovo-Rodrigues L, Schneider BC, Martins-Silva T, Del-Ponte B, Loret De Mola C, Schuler-Faccini L, et al. Is intrauterine exposure to acetaminophen associated with emotional and hyperactivity problems during childhood? Findings from the 2004 Pelotas birth cohort. BMC Psychiatry. 2018;18(1):1–11. doi: 10.1186/s12888-017-1517-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
13.Lutz BH, Miranda VIA, Silveira MPT, Dal Pizzol T da S, Mengue SS, da Silveira MF, et al. Medication Use among Pregnant Women from the 2015 Pelotas (Brazil) Birth Cohort Study. Int J Environ Res Public Health. 2020;17(3):989. doi: 10.3390/ijerph17030989 [DOI] [PMC free article] [PubMed] [Google Scholar]
14.Guerra GCB, Silva AQB da, França LB, Assunção PMC, Cabral RX, Ferreira AA de A. Utilização de medicamentos durante a gravidez na cidade de Natal, Rio Grande do Norte, Brasil. Rev Bras Ginecol e Obs. 2008;30(1):12–8. [DOI] [PubMed] [Google Scholar]
15.Werler MM, Mitchell AA, Hernandez-Diaz S, Honein MA. Use of over-the-counter medications during pregnancy. Am J Obstet Gynecol. 2005. Sep;193(3):771–7. doi: 10.1016/j.ajog.2005.02.100 [DOI] [PubMed] [Google Scholar]
16.Rebordosa C, Kogevinas M, Horváth-Puhó E, Nørgård B, Morales M, Czeizel AE, et al. Acetaminophen use during pregnancy: effects on risk for congenital abnormalities. Am J Obstet Gynecol. 2008;198(2):178.e1-178.e7. doi: 10.1016/j.ajog.2007.08.040 [DOI] [PubMed] [Google Scholar]
17.Feldkamp ML, Meyer RE, Krikov S, Botto LD. Acetaminophen use in pregnancy and risk of birth defects: Findings from the national birth defects prevention study. Obstet Gynecol. 2010. Jan;115(1):109–15. doi: 10.1097/AOG.0b013e3181c52616 [DOI] [PubMed] [Google Scholar]
18.Mašková J, Šípek A, Kollár P. A population-based case control study of congenital abnormalities and medication use during pregnancy using the Czech National Register of congenital abnormalities. Cent Eur J Med. 2011;6(4):435–41. [Google Scholar]
19.Rebordosa C, Kogevinas M, Bech BH, Sorensen HT, Olsen J. Use of acetaminophen during pregnancy and risk of adverse pregnancy outcomes. Int J Epidemiol. 2009;38(3):706–14. doi: 10.1093/ije/dyp151 [DOI] [PubMed] [Google Scholar]
20.Li D-K. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ. 2003. Aug 14;327(7411):368–0. doi: 10.1136/bmj.327.7411.368 [DOI] [PMC free article] [PubMed] [Google Scholar]
21.Arneja J, Hung RJ, Seeto RA, Knight JA, Hewko SL, Bocking A, et al. Association between maternal acetaminophen use and adverse birth outcomes in a pregnancy and birth cohort. Pediatr Res. 2020;87(7):1263–9. doi: 10.1038/s41390-019-0726-8 [DOI] [PubMed] [Google Scholar]
22.Czeizel AE, Dudás I, Puhó E. Short-term paracetamol therapy during pregnancy and a lower rate of preterm birth. Paediatr Perinat Epidemiol. 2005;19(2):106–11. doi: 10.1111/j.1365-3016.2005.00631.x [DOI] [PubMed] [Google Scholar]
23.Thulstrup AM, Sørensen HT, Nielsen GL, Andersen L, Barrett D, Vilstrup H, et al. Fetal growth and adverse birth outcomes in women receiving prescriptions for acetaminophen during pregnancy. EuroMap Study Group. Am J Perinatol. 1999;16(7):321–6. doi: 10.1055/s-2007-993879 [DOI] [PubMed] [Google Scholar]
24.Nitsche JF, Patil AS, Langman LJ, Penn HJ, Derleth D, Watson WJ, et al. Transplacental Passage of Acetaminophen in Term Pregnancy. Am J Perinatol. 2017;34(6):541–3. doi: 10.1055/s-0036-1593845 [DOI] [PubMed] [Google Scholar]
25.Instituto Brasileiro de Geografia e Estatística. Censo Demográfico—2010: Características da população e dos domicílios [Internet]. 2011. Available from: http://cidades.ibge.gov.br/painel/painel.php?lang=&codmun=292870&search=bahia%7Csantoantonio-de-jesus%7Cinfograficos:-dados-gerais-do-municipio.
26.DATASUS. Departamento de Informática do SUS, DATASUS. Informações de Saúde, Estatísticas Vitais: banco de dados [Internet]. Nov 5, 2017. Available from: http://datasus.saude.gov.br/index.php?option=com_content&view=article&id=152.
27.Fagundes AA, Barros DC, Duar HA, Sardinha LMV, Pereira MM, Leão MM. Vigilância alimentar e nutricional—Sisvan : orientações básicas para a coleta, processamento, análise de dados e informação em serviços de saúde. Brasília; 2004. [Google Scholar]
28.Quinn J-A, Munoz FM, Gonik B, Frau L, Cutland C, Mallett-Moore T, et al. Preterm birth: Case definition & guidelines for data collection, analysis, and presentation of immunisation safety data. Vaccine. 2016;34(49):6047–56. doi: 10.1016/j.vaccine.2016.03.045 [DOI] [PMC free article] [PubMed] [Google Scholar]
29.World Health Organization. Global Nutrition Targets 2025: Low birth weight policy brief. WHO; [Internet]. 2014;1–8. Available from: https://apps.who.int/iris/handle/10665/149020. [Google Scholar]
30.Schlaudecker EP, Munoz FM, Bardají A, Boghossian NS, Khalil A, Mousa H, et al. Small for gestational age: Case definition & guidelines for data collection, analysis, and presentation of maternal immunisation safety data. Vaccine. 2017;35(48 Pt A):6518–28. doi: 10.1016/j.vaccine.2017.01.040 [DOI] [PMC free article] [PubMed] [Google Scholar]
31.Dathe K, Padberg S, Hultzsch S, Meixner K, Tissen-Diabaté T, Meister R, et al. Metamizole use during first trimester-A prospective observational cohort study on pregnancy outcome. Pharmacoepidemiol Drug Saf. 2017;26(10):1197–204. doi: 10.1002/pds.4277 [DOI] [PubMed] [Google Scholar]
32.Gómez-Duarte OG. Is it time to restrict the clinical use of dipyrone? Colomb J Anesthesiol. 2019;47(2):81–3. [Google Scholar]
33.Migliore E, Zugna D, Galassi C, Merletti F, Gagliardi L, Rasero L, et al. Prenatal Paracetamol Exposure and Wheezing in Childhood: Causation or Confounding? PLoS One. 2015;10(8):e0135775. doi: 10.1371/journal.pone.0135775 [DOI] [PMC free article] [PubMed] [Google Scholar]
34.Rebordosa C, Zelop CM, Kogevinas M, Sørensen HT, Olsen J. Use of acetaminophen during pregnancy and risk of preeclampsia, hypertensive and vascular disorders: A birth cohort study. J Matern Neonatal Med. 2010;23(5):371–8. doi: 10.3109/14767050903334877 [DOI] [PubMed] [Google Scholar]
35.O’Brien WF, Krammer J, O’Leary TD, Mastrogiannis DS. The effect of acetaminophen on prostacyclin production in pregnant women. Am J Obstet Gynecol. 1993;168(4):1164–9. doi: 10.1016/0002-9378(93)90362-m [DOI] [PubMed] [Google Scholar]
36.Temu TB, Masenga G, Obure J, Mosha D, Mahande MJ. Maternal and obstetric risk factors associated with preterm delivery at a referral hospital in northern-eastern Tanzania. Asian Pacific J Reprod. 2016;5(5):365–70. [Google Scholar]
37.Alijahan R, Hazrati S, Mirzarahimi M, Pourfarzi F, Hadi PA. Prevalence and risk factors associated with preterm birth in Ardabil, Iran. Iran J Reprod Med. 2014;12(1):47–56. [PMC free article] [PubMed] [Google Scholar]
38.Jeena PM, Asharam K, Mitku AA, Naidoo P, Naidoo RN. Maternal demographic and antenatal factors, low birth weight and preterm birth: findings from the mother and child in the environment (MACE) birth cohort, Durban, South Africa. BMC Pregnancy Childbirth. 2020;20(1). doi: 10.1186/s12884-020-03328-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
39.Ko TJ, Tsai LY, Chu LC, Yeh SJ, Leung C, Chen CY, et al. Parental smoking during pregnancy and its association with low birth weight, small for gestational age, and preterm birth offspring: A birth cohort study. Pediatr Neonatol. 2014;55(1):20–7. doi: 10.1016/j.pedneo.2013.05.005 [DOI] [PubMed] [Google Scholar]
40.Chang YK, Tseng YT, Chen KT. The epidemiologic characteristics and associated risk factors of preterm birth from 2004 to 2013 in Taiwan. BMC Pregnancy Childbirth. 2020;20(1). doi: 10.1186/s12884-020-02903-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
41.Gunn JKL, Rosales CB, Center KE, Nuñez A, Gibson SJ, Christ C, et al. Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. BMJ Open. 2016;6(4):e009986. doi: 10.1136/bmjopen-2015-009986 [DOI] [PMC free article] [PubMed] [Google Scholar]

PLoS One. doi: 10.1371/journal.pone.0267270.r001

Decision Letter 0

Linglin Xie

8 Mar 2022

PONE-D-22-00646ASSOCIATION BETWEEN PARACETAMOL USE DURING PREGNANCY AND PERINATAL OUTCOMES: PROSPECTIVE NISAMI COHORTPLOS ONE

Dear Dr. Castro,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Apr 22 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Linglin Xie

Academic Editor

PLOS ONE

Journal Requirements:

1. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please amend your current ethics statement to address the following concerns:

a) Did participants provide their written or verbal informed consent to participate in this study?

b) If consent was verbal, please explain i) why written consent was not obtained, ii) how you documented participant consent, and iii) whether the ethics committees/IRB approved this consent procedure.

3. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The manuscript is technically sound but there is a great need to review the English language. Limitations have been stated. There is also need to state the strength of the study. Rationale for sample size has not been stated

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Emmanuel Ugwa

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Apr 18;17(4):e0267270. doi: 10.1371/journal.pone.0267270.r002

Author response to Decision Letter 0

17 Mar 2022

1. The manuscript is technically sound but there is a great need to review the English language.

Answer: As suggested by the reviewer, we revised the manuscript considering the reviewer's comments and we carried out the English proofreading.

2. Limitations have been stated. There is also need to state the strength of the study.

Answer: We agree with the reviewer and added the strengths of our study in the paper.

“One of the strengths of this study is the use of a standardized and tested questionnaire, standardization of data collection, and data validation. Another strength is the prospective design of the cohort, in which interviews were conducted during the prenatal period rather than only at delivery.” Page 14, lines 278-281 – section “Strengths and Limitations”.

3. Rationale for sample size has not been stated.

Answer: We agree with the reviewer on the need to explain the rationale for our sample size and included this information in the text.

First, we explained the sample size calculation of NISAMI cohort. “The sample size calculation of the NISAMI cohort was previously described [11]. In summary, the sample selection was based on a prevalence of 50%, a precision of 4%; confidence level of 95%, and 10% for possible losses. The minimum sample required to ensure statistical significance and 80% power was 891 pregnant women, yet the total sample included 1,091 women.” Page 4, lines 86-90 – section “Methods”.

Later, we described the total cohort population that originated our study sample. “From June 2012 to February 2014, 1,091 pregnant women met the original study selection criteria. A total of 760 (69.7%) women reported taking medication in the 15 days before the interviews and were included in this study.” Page 7, lines 152-154 – section “Results”.

Finally, we describe the reason why we adopted paracetamol use in the 15 days before the interview as a criterion for inclusion in our analyzes. “Considering that paracetamol can be taken both by prescription and self-medication, consumption could be underestimated due to memory bias and underreporting.” Page 14-15, lines 282-286 – section “Strengths and Limitations”.

Attachment

Submitted filename: Reviewer_Responses_Submission.docx

Click here for additional data file.^{(22.3KB, docx)}

PLoS One. doi: 10.1371/journal.pone.0267270.r003

Decision Letter 1

Linglin Xie

6 Apr 2022

ASSOCIATION BETWEEN PARACETAMOL USE DURING PREGNANCY AND PERINATAL OUTCOMES: PROSPECTIVE NISAMI COHORT

PONE-D-22-00646R1

Dear Dr. Castro,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Linglin Xie

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

Reviewer #1: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

Reviewer #1: Yes

**********

6. Review Comments to the Author

Reviewer #1: good work. note however that paracetamol safety at clinical doses are unequivocally safe. it is important to note that these findings are not new.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Emmanuel Ugwa, PhD, FWACS

PLoS One. doi: 10.1371/journal.pone.0267270.r004

Acceptance letter

Linglin Xie

8 Apr 2022

PONE-D-22-00646R1

ASSOCIATION BETWEEN PARACETAMOL USE DURING PREGNANCY AND PERINATAL OUTCOMES: PROSPECTIVE NISAMI COHORT

Dear Dr. Castro:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Linglin Xie

Academic Editor

PLOS ONE

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

S1 Database

(XLSX)

Click here for additional data file.^{(100.6KB, xlsx)}

Attachment

Submitted filename: Reviewer_Responses_Submission.docx

Click here for additional data file.^{(22.3KB, docx)}

Data Availability Statement

All relevant data are within the paper and its Supporting Information files.

[pone.0267270.ref001] 1.Grzeskowiak LE, Gilbert AL, Morrison JL. Exposed or not exposed? Exploring exposure classification in studies using administrative data to investigate outcomes following medication use during pregnancy. Eur J Clin Pharmacol. 2012;68(5):459–67. doi: 10.1007/s00228-011-1154-9 [DOI] [PubMed] [Google Scholar]

[pone.0267270.ref002] 2.Adam MP, Polifka JE, Friedman JMM. Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet Part C Semin Med Genet. 2011;157(3):175–82. doi: 10.1002/ajmg.c.30313 [DOI] [PubMed] [Google Scholar]

[pone.0267270.ref003] 3.Daw JR, Hanley GE, Greyson DL, Morgan SG. Prescription drug use during pregnancy in developed countries: a systematic review. Pharmacoepidemiol Drug Saf. 2011. Jul;20(9):895–902. doi: 10.1002/pds.2184 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0267270.ref004] 4.Sinclair SM, Miller RK, Chambers C, Cooper EM. Medication Safety During Pregnancy: Improving Evidence‐Based Practice. J Midwifery Womens Health. 2016;61(1):52–67. doi: 10.1111/jmwh.12358 [DOI] [PubMed] [Google Scholar]

[pone.0267270.ref005] 5.Allegaert K, van den Anker JN. Perinatal and neonatal use of paracetamol for pain relief. Semin Fetal Neonatal Med. 2017;22(5):308–13. doi: 10.1016/j.siny.2017.07.006 [DOI] [PubMed] [Google Scholar]

[pone.0267270.ref006] 6.Castillo Barrio B, Bravo Laguna MC, de la Calle Fernández M, Pellicer Martínez A. Consumption of paracetamol during pregnancy. An Pediatr. 2020;93(3):196–7. doi: 10.1016/j.anpedi.2019.12.016 [DOI] [PubMed] [Google Scholar]

[pone.0267270.ref007] 7.Benevent J, Hurault-Delarue C, Araujo M, Montastruc JL, Lacroix I, Damase-Michel C. POMME: The New Cohort to Evaluate Long-Term Effects After Prenatal Medicine Exposure. Drug Saf. 2019;42(1):45–54. doi: 10.1007/s40264-018-0712-9 [DOI] [PubMed] [Google Scholar]

[pone.0267270.ref008] 8.Volqvartz T, Vestergaard AL, Aagaard SK, Andreasen MF, Lesnikova I, Uldbjerg N, et al. Use of stimulants, over‐the‐counter and prescription drugs among Danish pregnant women. Basic Clin Pharmacol Toxicol. 2020;bcpt.13396. doi: 10.1111/bcpt.13396 [DOI] [PubMed] [Google Scholar]

[pone.0267270.ref009] 9.Bandoli G, Palmsten K, Chambers C. Acetaminophen use in pregnancy: Examining prevalence, timing, and indication of use in a prospective birth cohort. Paediatr Perinat Epidemiol. 2020;34(3):237–46. doi: 10.1111/ppe.12595 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0267270.ref010] 10.Ystrom E, Gustavson K, Brandlistuen RE, Knudsen GP, Magnus P, Susser E, et al. Prenatal Exposure to Acetaminophen and Risk of ADHD. Pediatrics. 2017;140(5):e20163840. doi: 10.1542/peds.2016-3840 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0267270.ref011] 11.Costa DB, Coelho HLL, Santos DB. Utilização de medicamentos antes e durante a gestação: prevalência e fatores associados. Cad Saude Publica. 2017;33(2). [DOI] [PubMed] [Google Scholar]

[pone.0267270.ref012] 12.Tovo-Rodrigues L, Schneider BC, Martins-Silva T, Del-Ponte B, Loret De Mola C, Schuler-Faccini L, et al. Is intrauterine exposure to acetaminophen associated with emotional and hyperactivity problems during childhood? Findings from the 2004 Pelotas birth cohort. BMC Psychiatry. 2018;18(1):1–11. doi: 10.1186/s12888-017-1517-6 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0267270.ref013] 13.Lutz BH, Miranda VIA, Silveira MPT, Dal Pizzol T da S, Mengue SS, da Silveira MF, et al. Medication Use among Pregnant Women from the 2015 Pelotas (Brazil) Birth Cohort Study. Int J Environ Res Public Health. 2020;17(3):989. doi: 10.3390/ijerph17030989 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0267270.ref014] 14.Guerra GCB, Silva AQB da, França LB, Assunção PMC, Cabral RX, Ferreira AA de A. Utilização de medicamentos durante a gravidez na cidade de Natal, Rio Grande do Norte, Brasil. Rev Bras Ginecol e Obs. 2008;30(1):12–8. [DOI] [PubMed] [Google Scholar]

[pone.0267270.ref015] 15.Werler MM, Mitchell AA, Hernandez-Diaz S, Honein MA. Use of over-the-counter medications during pregnancy. Am J Obstet Gynecol. 2005. Sep;193(3):771–7. doi: 10.1016/j.ajog.2005.02.100 [DOI] [PubMed] [Google Scholar]

[pone.0267270.ref016] 16.Rebordosa C, Kogevinas M, Horváth-Puhó E, Nørgård B, Morales M, Czeizel AE, et al. Acetaminophen use during pregnancy: effects on risk for congenital abnormalities. Am J Obstet Gynecol. 2008;198(2):178.e1-178.e7. doi: 10.1016/j.ajog.2007.08.040 [DOI] [PubMed] [Google Scholar]

[pone.0267270.ref017] 17.Feldkamp ML, Meyer RE, Krikov S, Botto LD. Acetaminophen use in pregnancy and risk of birth defects: Findings from the national birth defects prevention study. Obstet Gynecol. 2010. Jan;115(1):109–15. doi: 10.1097/AOG.0b013e3181c52616 [DOI] [PubMed] [Google Scholar]

[pone.0267270.ref018] 18.Mašková J, Šípek A, Kollár P. A population-based case control study of congenital abnormalities and medication use during pregnancy using the Czech National Register of congenital abnormalities. Cent Eur J Med. 2011;6(4):435–41. [Google Scholar]

[pone.0267270.ref019] 19.Rebordosa C, Kogevinas M, Bech BH, Sorensen HT, Olsen J. Use of acetaminophen during pregnancy and risk of adverse pregnancy outcomes. Int J Epidemiol. 2009;38(3):706–14. doi: 10.1093/ije/dyp151 [DOI] [PubMed] [Google Scholar]

[pone.0267270.ref020] 20.Li D-K. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ. 2003. Aug 14;327(7411):368–0. doi: 10.1136/bmj.327.7411.368 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0267270.ref021] 21.Arneja J, Hung RJ, Seeto RA, Knight JA, Hewko SL, Bocking A, et al. Association between maternal acetaminophen use and adverse birth outcomes in a pregnancy and birth cohort. Pediatr Res. 2020;87(7):1263–9. doi: 10.1038/s41390-019-0726-8 [DOI] [PubMed] [Google Scholar]

[pone.0267270.ref022] 22.Czeizel AE, Dudás I, Puhó E. Short-term paracetamol therapy during pregnancy and a lower rate of preterm birth. Paediatr Perinat Epidemiol. 2005;19(2):106–11. doi: 10.1111/j.1365-3016.2005.00631.x [DOI] [PubMed] [Google Scholar]

[pone.0267270.ref023] 23.Thulstrup AM, Sørensen HT, Nielsen GL, Andersen L, Barrett D, Vilstrup H, et al. Fetal growth and adverse birth outcomes in women receiving prescriptions for acetaminophen during pregnancy. EuroMap Study Group. Am J Perinatol. 1999;16(7):321–6. doi: 10.1055/s-2007-993879 [DOI] [PubMed] [Google Scholar]

[pone.0267270.ref024] 24.Nitsche JF, Patil AS, Langman LJ, Penn HJ, Derleth D, Watson WJ, et al. Transplacental Passage of Acetaminophen in Term Pregnancy. Am J Perinatol. 2017;34(6):541–3. doi: 10.1055/s-0036-1593845 [DOI] [PubMed] [Google Scholar]

[pone.0267270.ref025] 25.Instituto Brasileiro de Geografia e Estatística. Censo Demográfico—2010: Características da população e dos domicílios [Internet]. 2011. Available from: http://cidades.ibge.gov.br/painel/painel.php?lang=&codmun=292870&search=bahia%7Csantoantonio-de-jesus%7Cinfograficos:-dados-gerais-do-municipio.

[pone.0267270.ref026] 26.DATASUS. Departamento de Informática do SUS, DATASUS. Informações de Saúde, Estatísticas Vitais: banco de dados [Internet]. Nov 5, 2017. Available from: http://datasus.saude.gov.br/index.php?option=com_content&view=article&id=152.

[pone.0267270.ref027] 27.Fagundes AA, Barros DC, Duar HA, Sardinha LMV, Pereira MM, Leão MM. Vigilância alimentar e nutricional—Sisvan : orientações básicas para a coleta, processamento, análise de dados e informação em serviços de saúde. Brasília; 2004. [Google Scholar]

[pone.0267270.ref028] 28.Quinn J-A, Munoz FM, Gonik B, Frau L, Cutland C, Mallett-Moore T, et al. Preterm birth: Case definition & guidelines for data collection, analysis, and presentation of immunisation safety data. Vaccine. 2016;34(49):6047–56. doi: 10.1016/j.vaccine.2016.03.045 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0267270.ref029] 29.World Health Organization. Global Nutrition Targets 2025: Low birth weight policy brief. WHO; [Internet]. 2014;1–8. Available from: https://apps.who.int/iris/handle/10665/149020. [Google Scholar]

[pone.0267270.ref030] 30.Schlaudecker EP, Munoz FM, Bardají A, Boghossian NS, Khalil A, Mousa H, et al. Small for gestational age: Case definition & guidelines for data collection, analysis, and presentation of maternal immunisation safety data. Vaccine. 2017;35(48 Pt A):6518–28. doi: 10.1016/j.vaccine.2017.01.040 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0267270.ref031] 31.Dathe K, Padberg S, Hultzsch S, Meixner K, Tissen-Diabaté T, Meister R, et al. Metamizole use during first trimester-A prospective observational cohort study on pregnancy outcome. Pharmacoepidemiol Drug Saf. 2017;26(10):1197–204. doi: 10.1002/pds.4277 [DOI] [PubMed] [Google Scholar]

[pone.0267270.ref032] 32.Gómez-Duarte OG. Is it time to restrict the clinical use of dipyrone? Colomb J Anesthesiol. 2019;47(2):81–3. [Google Scholar]

[pone.0267270.ref033] 33.Migliore E, Zugna D, Galassi C, Merletti F, Gagliardi L, Rasero L, et al. Prenatal Paracetamol Exposure and Wheezing in Childhood: Causation or Confounding? PLoS One. 2015;10(8):e0135775. doi: 10.1371/journal.pone.0135775 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0267270.ref034] 34.Rebordosa C, Zelop CM, Kogevinas M, Sørensen HT, Olsen J. Use of acetaminophen during pregnancy and risk of preeclampsia, hypertensive and vascular disorders: A birth cohort study. J Matern Neonatal Med. 2010;23(5):371–8. doi: 10.3109/14767050903334877 [DOI] [PubMed] [Google Scholar]

[pone.0267270.ref035] 35.O’Brien WF, Krammer J, O’Leary TD, Mastrogiannis DS. The effect of acetaminophen on prostacyclin production in pregnant women. Am J Obstet Gynecol. 1993;168(4):1164–9. doi: 10.1016/0002-9378(93)90362-m [DOI] [PubMed] [Google Scholar]

[pone.0267270.ref036] 36.Temu TB, Masenga G, Obure J, Mosha D, Mahande MJ. Maternal and obstetric risk factors associated with preterm delivery at a referral hospital in northern-eastern Tanzania. Asian Pacific J Reprod. 2016;5(5):365–70. [Google Scholar]

[pone.0267270.ref037] 37.Alijahan R, Hazrati S, Mirzarahimi M, Pourfarzi F, Hadi PA. Prevalence and risk factors associated with preterm birth in Ardabil, Iran. Iran J Reprod Med. 2014;12(1):47–56. [PMC free article] [PubMed] [Google Scholar]

[pone.0267270.ref038] 38.Jeena PM, Asharam K, Mitku AA, Naidoo P, Naidoo RN. Maternal demographic and antenatal factors, low birth weight and preterm birth: findings from the mother and child in the environment (MACE) birth cohort, Durban, South Africa. BMC Pregnancy Childbirth. 2020;20(1). doi: 10.1186/s12884-020-03328-6 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0267270.ref039] 39.Ko TJ, Tsai LY, Chu LC, Yeh SJ, Leung C, Chen CY, et al. Parental smoking during pregnancy and its association with low birth weight, small for gestational age, and preterm birth offspring: A birth cohort study. Pediatr Neonatol. 2014;55(1):20–7. doi: 10.1016/j.pedneo.2013.05.005 [DOI] [PubMed] [Google Scholar]

[pone.0267270.ref040] 40.Chang YK, Tseng YT, Chen KT. The epidemiologic characteristics and associated risk factors of preterm birth from 2004 to 2013 in Taiwan. BMC Pregnancy Childbirth. 2020;20(1). doi: 10.1186/s12884-020-02903-1 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0267270.ref041] 41.Gunn JKL, Rosales CB, Center KE, Nuñez A, Gibson SJ, Christ C, et al. Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. BMJ Open. 2016;6(4):e009986. doi: 10.1136/bmjopen-2015-009986 [DOI] [PMC free article] [PubMed] [Google Scholar]

PERMALINK

Association between paracetamol use during pregnancy and perinatal outcomes: Prospective NISAMI cohort

Caroline Tianeze de Castro

Marcos Pereira

Djanilson Barbosa dos Santos

Roles

Abstract

Background

Methods and findings

Conclusions

Introduction

Methods

Study design

Data source

Exposure

Outcomes

Covariates

Statistical analysis

Ethics statement

Results

Cohort characteristics

Table 1. Characteristics of the study population.

Paracetamol use and perinatal outcomes

Fig 1. Paracetamol use according to trimester of exposure and perinatal outcomes.

Table 2. Odds Ratios for preterm birth, low birth weight, and small for gestational age in women exposed to paracetamol during pregnancy.

Discussion

Strengths and limitations

Conclusions

Supporting information

Data Availability

Funding Statement

References

Decision Letter 0

Linglin Xie

Roles

Author response to Decision Letter 0

Decision Letter 1

Linglin Xie

Roles

Acceptance letter

Linglin Xie

Roles

Associated Data

Supplementary Materials

Data Availability Statement

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases